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Abstract
Background: While South Africa spends approximately 7.4% of GDP on healthcare, only 43% of these funds are
spent in the public system, which is tasked with the provision of care to the majority of the population including a
large proportion of those in need of antiretroviral treatment (ART). South Africa is currently debating the
introduction of a National Health Insurance (NHI) system. Because such a universal health system could mean
increased public healthcare funding and improved access to human resources, it could improve the sustainability
of ART provision. This paper considers the minimum resources that would be required to achieve the proposed
universal health system and contrasts these with the costs of scaled up access to ART between 2010 and 2020.
Methods: The costs of ART and universal coverage (UC) are assessed through multiplying unit costs, utilization and
estimates of the population in need during each year of the planning cycle. Costs are from the provider’s
perspective reflected in real 2007 prices.
Results: The annual costs of providing ART increase from US$1 billion in 2010 to US$3.6 billion in 2020. If increases
in funding to public healthcare only keep pace with projected real GDP growth, then close to 30% of these
resources would be required for ART by 2020. However, an increase in the public healthcare resource envelope
from 3.2% to 5%-6% of GDP would be sufficient to finance both ART and other services under a universal system
(if based on a largely public sector model) and the annual costs of ART would not exceed 15% of the universal
health system budget.
Conclusions: Responding to the HIV-epidemic is one of the many challenges currently facing South Africa.
Whether this response becomes a “resource for democracy” or whether it undermines social cohesiveness within
poor communities and between rich and poor communities will be partially determined by the steps that are
taken during the next ten years. While the introduction of a universal system will be complex, it could generate a
health system responsive to the needs of all South Africans.
Introduction
As the country with the highest number of HIV-infected
people – accounting for a total of 17% of the global HIV
burden [1] – treatment for HIV/AIDS in South Africa is
a classic example of resource allocation in the face of
highly constrained budgets. A key issue is that every
treatment option for HIV has a large opportunity cost,
particularly if the treatment strategy intends to provide
coverage for a high percentage of those in need. This is
partly because of the scale of the epidemic, and partly
because HIV/AIDS is a new burden of disease. The allo-
cation of resources to HIV-treatment is therefore not
just about changing the scale at which the HIV-
treatment programme is operating, but also about the
creation of a new healthcare programme with associated
training of health personnel, and investments in infra-
structure, medical equipment, drug procurement and
delivery systems.
In the recent “HIV&AIDS and STI National Strategic
Plan” [2] the South African government committed to
providing “an appropriate package of treatment, care
and support services to 80 per cent of people living with
HIV… by 2011” (p. 64). This “appropriate package” was
defined, following the most recent “National Antiretro-
viral Treatment Guidelines” [3] to mean that antiretro-
viral treatment (ART) should be started (i.e. is needed)
in adults once their CD4 count has fallen below
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200 cells/μl and/or they have an AIDS diagnosis. The
commitments contained within the national strategic
plan are also argued to be guided by a number of princi-
ples including “tackling inequality and poverty” and
“promoting equality for women and girls” (p. 60).
Although no explicit equity goal is stated, the focus on
increasing and sustaining high coverage could be argued
to relate to horizontal equity – the equal treatment of
equals – while the latter focus on guiding principles
could be interpreted as ensuring vertical equity – the
unequal but equitable treatment of unequals [4]. To
date, there are around 700,000 people who have started
on ART in South Africa [5] which means that this is by
far the world’s largest programme. During 2008, just
over 40% of new need was met.
South Africa’s health system includes both public and
private financing and delivery. ART has been available
in the private sector since as early as 1998, primarily via
disease management programmes in private health
insurance schemes (known locally as medical schemes).
By 2004, when public sector ART provision began, well
over 70% of those on ART in the country were in pri-
vate care. However, by 2008 the situation had reversed
with over 80% treated in the public sector [6,7]. This
trend is likely to continue, with the implication that the
public sector faces the majority of the HIV-related dis-
ease burden, with potentially major repercussions for
affordability [8].
In terms of the overall resources available, the respect-
able 7.4% of GDP spent on healthcare in 2008 masks a
highly unequal distribution of resources between the
public and private healthcare sectors. Approximately
3.2% of GDP is spent within the public sector where the
majority poor access care to the value of US$258 per
person per annum. About 84% of the population is
entirely dependent on the public sector for specialist
and inpatient care. The other 16% of the population is
covered by voluntary private health insurance and uses
private sector services to the value of $1,363 per person
per annum [Updated from: 9]. A further 1% of GDP is
spent out-of-pocket on private sector providers, both in
the form of co-payments by the insured and direct pay-
ments to private primary care providers (general practi-
tioners and retail pharmacies) by a limited number of
the uninsured. In addition, while substantial donor fund-
ing is available to support the scaling-up of ART, this
amounts to only approximately 2% of the overall
resource envelope available in the public health system
(personal communication, Dr Mark Blecher, National
Treasury South Africa).
Although funding for HIV-treatment has increased
dramatically in the past 5 years in the public health sec-
tor, a programme of ambitious budget deficit reductions
combined with personal income tax rate reductions has
meant that the overall funding levels in the public health
sector have been relatively stagnant until recently [10].
Additional file 1 illustrates how real per capita spending
levels in the public sector actually declined from 1996
and only returned to 1996 levels in 2005, while spending
via private voluntary health insurance increased rapidly
in real terms leading to an increase in the public-private
mix gap from a three-fold to more than a five-fold dif-
ference between 1996 and 2008. Service delivery in the
public sector is increasingly hampered by large human
resource shortages. Trends in human resources followed
a similar pattern to real expenditure, with total staffing
in the public health sector declining from about 251,000
in 1997 to about 215,000 in the early 2000s and return-
ing to 251,000 by 2007/08. A recent report estimated
that an additional 64,000 staff were required in 2007/08
to keep pace with the growth in the population depen-
dent on the public health sector while 80,000 were
required to accommodate both population growth and
the growth in the burden of disease – largely related to
HIV/AIDS [11].
There is growing consensus that the public health sec-
tor is inadequately resourced and there appears to be a
commitment to gradually increasing public funding of
health services to closer to 5% of GDP [11]. The context
within which this is envisaged to happen is the intro-
duction of a so-called ‘National Health Insurance
(NHI)’, which the ruling party – the African National
Congress (ANC) – committed itself to at its 2007 Polok-
wane Policy Conference and again during the 2009 elec-
tions. The ANC has been working on proposals for a
NHI ‘behind closed doors’ and to date, no formal propo-
sals have been put forward by government. Thus, the
likely NHI design is unknown at this point. However,
limited available information indicates that the broad
vision is to focus energies primarily on rebuilding the
public health sector to the point that it once again
becomes the provider of choice of the vast majority of
South Africans. This would be achieved by gradually,
but substantially, increasing allocations from general tax
revenue to the health sector as well as possibly introdu-
cing a compulsory NHI contribution for all formal sec-
tor employees. These funds would be pooled to promote
access to publicly-funded health services that benefit all
South Africans. It has been proposed that the NHI
would purchase services for the population from accre-
dited healthcare providers, which could potentially
include both public and private sector providers. It
appears that the existing private voluntary health insur-
ance schemes would continue, but may diminish in size
over time.
The precise nature of future health system change is
still unclear and will undoubtedly be influenced by the
preferences of powerful stakeholders. There is also
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debate about whether the term NHI appropriately
reflects the health system change that is envisaged for
South Africa. What is clear though is that there is gov-
ernment commitment to achieving universal coverage.
This objective is internationally supported, as demon-
strated by the 2005 World Health Assembly resolution
calling on member states to pursue universal coverage
in their health systems [12]. The core elements of the
concept of universal coverage are to provide financial
protection against healthcare costs as well as ensuring
access to quality healthcare for all when needed. In this
paper, we prefer to refer to proposed health system
change in South Africa as universal coverage (UC)
reform. This is not only because the precise design of
health system reform is yet to be finalised but also
because, while we strongly support the goal of moving
towards a universal health system, the term NHI fre-
quently conjures up preconceived notions of a very spe-
cific health insurance model. We recognise that there
are different ways in which UC can be achieved and
that progress towards this goal must be appropriate
within the South African context.
To date, most countries that have faced a comparable
magnitude of AIDS epidemic, either in terms of the
number of HIV-infected people such as India or HIV
prevalence such as Swaziland, Botswana, Lesotho,
Zimbabwe and Namibia [1] have relied heavily on donor
funding for scaling up access to ART. A particularly
striking example is that of Botswana, which received
considerable external resources and technical support in
scaling up equitable access to ART in a relatively short
period of time. However, some countries cannot rely on
external or donor support to the same extent. For exam-
ple, South Africa is not regarded as a priority country
for donor grants due to its relatively high level of eco-
nomic development, while Zimbabwe has faced a mas-
sive decline in donor funding in protest against
Mugabe’s rule. Zimbabwe has attempted to generate
additional domestic funding through an AIDS levy, of
3% additional personal and company income tax [13].
South Africa is considering introducing UC reform with
the aim of achieving universal health service coverage,
including ART services, based on domestic public
funding.
While donor grants will continue to be a critical fund-
ing source for health systems in many low- and middle-
income countries for the foreseeable future, particularly
in terms of funding AIDS interventions, there is a grow-
ing awareness of the need to expand domestic funding
for health services. For example, the commitment by
African Heads of State at a meeting in Abuja in 2001 to
devote a minimum of 15% of government funds to the
health sector was explicitly taken in recognition of the
need to increase government spending on health
services in order to address the massive burden of HIV/
AIDS, TB and other infectious diseases facing countries
in Africa [14]. More recently, the “Taskforce on Innova-
tive International Financing for Health Systems” [15]
has pointed to the need for more domestic resources,
reduction in fragmentation of funding flows as well as
an overall focus on health systems’ strengthening in
order to achieve the health Millennium Development
Goals (MDGs) which include the scaling up of HIV-
treatment.
This consideration of funding scaled-up AIDS inter-
ventions in South Africa in the context of increased
public domestic funding through the proposed UC
reform is therefore potentially of considerable relevance
to other countries which face a heavy AIDS burden and
are seeking to respond to the World Health Assembly’s
call for universal health service coverage through pre-
payment funding mechanisms [16]. Given this back-
ground, the objective of this paper is to explore the
affordability of achieving high coverage of those in need
of ART in South Africa by and beyond 2020 within the
context of the proposed UC reform.
In the remainder of the paper, two scenarios are mod-
eled. In the first, the costs of scaled up access to ART
are contextualized relative to a status quo scenario that
assumes that the real growth in public healthcare
resources keeps pace with projections of real growth in
GDP. In the second scenario, the costs of scaled up
access to ART as well as the costs of an adequately
funded UC system are calculated. In what follows, the
methods section outlines the data that have been used
to estimate the costs of scaling up ART and the
resource requirements for the UC system. Total and
annual costs of ART are presented in the results section
and compared to the status quo scenario and to pro-
posed expenditure levels required within a universal
health system. The final section includes a discussion
and conclusions.
Methods
Costs of scaling up ART
Setting
The cost, utilization and outcomes data that inform this
costing have been derived from the long-term follow-up
of a cohort of adult HIV-positive patients receiving care
in the sub-district of Khayelitsha, a largely informal area
on the outskirts of Cape Town. In April 2000, three
HIV clinics were opened in public facilities to provide
treatment and prophylaxis of HIV-related and opportu-
nistic infections and events, counselling and support
groups for HIV-positive people. Acute infections were
managed at the clinics while suspected tuberculosis (TB)
cases were referred to TB facilities and severely ill
patients to secondary and tertiary hospitals. In May
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2001, the service was extended to include ART. After
starting ART, patients continued to receive treatment
and prophylaxis for acute infections as well as appropri-
ate referrals for TB and hospital services.
Costing
The costing takes a public healthcare perspective in the
context of scaling-up a large new healthcare programme
over the long-run. Scaling-up requires medicines, labora-
tory investigations and other variable resources as well as
long-run investments aimed at increasing the capacity of
the healthcare system in order to provide the envisaged
quantity of care while at the same time avoiding the
crowding out of other priorities. The scope of costs
therefore includes both variable and fixed direct health-
care costs given that both have an opportunity cost in
this context. These costs were established for a full range
of HIV-related services including HIV clinic visits and
associated adherence support services, TB treatment and
both district and tertiary level inpatient care. Given that
unit costs within facilities can vary for a number of rea-
sons including potential economies or diseconomies of
scale, unit costs were calculated by pooling primary and
secondary data from full economic cost analyses of four
inpatient facilities, four ART clinics and four TB facilities
[17-21]. Public sector ARV costs (including delivery costs
to provincial depots) were sourced from the South
African national ARV tender [22] and laboratory investi-
gation costs were from the National Health Laboratory
Services. In line with South African ART guidelines [3],
patients receive stavudine, lamivudine and nevirapine or
efavirenz as the first-line regimen. In the first and sec-
ond-line treatment scenario, a patient failing the first-line
regimen receives zidovudine, didanosine and lopinavir/
ritonavir as second-line. CD4 and viral load monitoring
occurs about twice a year.
Healthcare utilisation
HIV clinic, laboratory and ARV utilisation was calcu-
lated from 1,729 patients with 2,229 ART patient years
of follow-up over a median follow-up of 1.03 years (IQR
0.68 – 1.70, max 4.08). Data on the use of inpatient and
tuberculosis care required extensive validation. This was
undertaken on 670 patients, with 693 ART patient-
years. Relatively high mortality in the early months of
ART and high rates of healthcare utilisation decreased
once immune recovery had been achieved. This variabil-
ity was captured directly from primary data. On the
other hand, healthcare utilisation could be expected to
increase for patients failing ART and dying. This was
captured through specifying a “cost of dying”, based on
a sample of 81 patients on ART who died of HIV-
related causes.
ART model
Markov modelling was used to extrapolate primary data
and to calculate the per-patient lifetime costs and
outcomes of treatment and the total costs of treating all
patients in need over the planning period. Separate
Markov states were specified for CD4 50-199 cells/μl,
and CD4 <50 cells/μl because these categories have
been shown to be associated with different mortality
rates in large cohort analyses [23,24]. Further heteroge-
neity between patients was observed to be related to the
amount of time the patient had been on ART – mortal-
ity rates decreased steadily from the time of starting
ART until the end of the follow-up period of 48
months. Similarly, the costs of healthcare are much
higher in the first year because patients are relatively ill
and could require inpatient care or TB treatment, are
undergoing frequent laboratory investigations as speci-
fied by South African “National Antiretroviral Treat-
ment Guidelines” (2004) and require more frequent
visits to the clinic.
To capture this heterogeneity, the CD4-based Markov
states were split into a number of temporary states,
known as tunnel states. The use of these allowed the
transition probabilities and costs to be varied as time on
ART increased. During the first 6 month period, tempor-
ary states were created for each Markov cycle and for
each CD4 category. After 6 months on ART, there was
no longer any significant difference in costs and out-
comes within CD4 strata, and these states were merged.
However, differences in mortality probabilities and costs
in relation to duration on ART were still significant,
necessitating the ongoing use of tunnel states between 6
and 48 months on treatment. After 6 months on ART,
the model included a probability of failing the first-line
regimen. If first-line treatment was failed, the patient
transitioned to the second-line regimen – the inclusion
of separate states for the second-line regimen is required
to capture the higher costs of these ARVs.
Transition probabilities
Transition probabilities are required to specify all rele-
vant movements between Markov states In the ART
models, these probabilities were estimated from Kaplan
Meier product limit estimates of survival for the same
1,729 patients receiving ART in the first 48 months of
the Khayelitsha programme, and extrapolated thereafter.
The probability of dying was calculated directly from
primary data and specified separately for each three-
month cycle over the first 6 months on treatment, per
6-month period for months 6-12 and per annual period
in months 12-24, 24-36 and 36-48 (no patients failed
first-line in the first six months). This allowed an accu-
rate specification of the decline in mortality over four
years on ART. Patients who were lost to follow-up were
conservatively treated statistically as deaths. The prob-
ability of transitioning to the second-line Markov states
was calculated from primary data separately for months
6-12, 12-24, 24-36 and 36-48. We extrapolated death
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and failure transition probabilities conservatively by
averaging over the full period of follow-up – this
achieves a lower life expectancy than if we had extrapo-
lated from later periods where far fewer deaths
occurred. Because life-expectancy might be higher in
pilot settings, the potential overestimate of mortality
would increase the generalizability of results to routine
services.
Additional details including unit costs, utilization esti-
mates, transition probabilities
And full validations of the model including extensive
multi-way and probabilistic sensitivity analyses have
been published elsewhere [25].
Estimating the costs of scaling-up ART
Calculating the costs of scaling-up is achieved by enter-
ing estimates of total patient numbers into the model
described above during each cycle of the planning per-
iod. The planning period is defined to start in 2004
which is when public sector ART provision began in
South Africa. While the focus of this article is on the
period from 2010 to 2020, the costs for patients who
started ART prior to this time who are still surviving
and remaining in care need to be included. Costs were
therefore based on the actual patient coverage achieved
from 2004 to 2008, patient coverage targets contained in
the government’s strategic plan from 2009 to 2011 and
after 2011, it has been assumed that the treatment cov-
erage target reached by that date would be maintained
until 2020. This is justifiable given that the 2011 target
was to reach full coverage of those in need. Under the
assumption that the government intends to fully fund
their HIV-treatment plan, then the results of this cost-
ing exercise give an indication of the likely budget or
resource envelope available for HIV-treatment over the
period of analysis. These estimates of patients in need
after 2012 have been extracted from the ASSA2003lite
model (the leading model used in South Africa to esti-
mate the total population with and without HIV/AIDS.
These data were derived from ASSA2003lite (release
060315) as downloaded from http://www.actuarialsoci-
ety.org.za in May 2009). Full details of the assumptions
of this model are available [26,27].
Costs were expressed in 2007 prices, converted to US
dollars using an average 2007 exchange rate (US$1=7.05
South African Rands) [28]. Inflation adjustments were
made using the consumer price index excluding mort-
gage bonds [29].
Costs of UC
The modeling of the resource requirements for a UC
health system draws on the SHIELD (Strategies for
Health Insurance for Equity in Less Developed coun-
tries) project. This project is considering a range of sce-
narios for health system change to address existing
inequities. The full range of scenarios, and extensive
sensitivity analyses for each scenario will soon be pub-
lished in full. The model presented here reflects what
could be termed a basic universal coverage scenario,
based on improved resourcing of public sector health
services. It can be regarded as the minimum resourcing
levels required for achieving universal coverage. This is
appropriate to use in this paper as the purpose of this
paper is not to critically evaluate alternative approaches
to achieving universal coverage, but to illustrate the
relative burden of ART costs within a universal health
system context. Thus, adopting a relatively conservative
approach to universal coverage resource requirements is
appropriate. The main assumptions and methods for
this model are described in detail in additional file 2.
There are three key variables in the model, which can
be described by the following equation (with each of the
three main variables disaggregated in various ways):
Total expenditure = population x service utilisation
rates x unit costs
As there are considerable differences in utilisation
rates between different age/sex groups, population and
utilisation data are disaggregated into the following age
groups: 0-4, 5-14, 15-49, 50-59 and 60+ years, expressed
separately for females and males.
This approach is in line with the standard interna-
tional approach to modelling future resource require-
ments with health system change, which is described as
follows:
“The general approach would be to assume that per-
sons of different age groups would use a certain
amount of services over a given period, and also to
make certain assumptions regarding the development
of prices over time. The multiplication of these utili-
zation rates and unit costs yields expenditure for
each type of service analysed. These expenditure sub-
totals are then added to arrive at total benefit expen-
diture with the system” [30].
Utilisation rates are also disaggregated for different
categories of services (primary healthcare visits and in-
and out-patient care at district, regional and tertiary or
central hospitals) and are specified as the number of vis-
its per person per year and number of inpatient days per
person per year. The unit costs for each of these differ-
ent services are specified as cost per visit and cost per
inpatient day.
The baseline age/sex utilisation rates for each type of
service were derived from a national household survey
conducted in 2008 which focussed exclusively on collect-
ing health and health service related information [31].
Current utilisation rates of public sector health ser-
vices are relatively low in South Africa. A number of
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detailed studies have been undertaken in the past which
have carefully calculated utilisation rate norms based on
a range of factors, including burden of disease and
drawing on international experience of health service
utilisation in well funded health systems. These studies
were drawn on to estimate future utilisation rates. In
the case of primary healthcare services, the ‘Need
Norms’ study undertaken by the Centre for Health Pol-
icy [32] was used, but was updated to account for
increased service requirements for those with HIV/AIDS
before they are eligible for ART. In the case of in- and
out-patient hospital services, the utilisation rates recom-
mended by the ‘Hospital Strategy Project’ were used
[33]. It was assumed that these utilisation levels would
be fully phased in by 2020.
Current unit costs were calculated by combining
information on expenditure in each public hospital in
South Africa (sourced from National Treasury) with
information on the number of inpatient days and outpa-
tient visits at each hospital (sourced from the Health
Information System database maintained by the national
Department of Health).
As indicated previously, the public health system is
currently under-resourced with real expenditure and
staffing levels not keeping pace with the growth in the
population dependent on public sector services (or with
the growing burden of disease in South Africa). A recent
study estimated that an additional US$3.3 billion is
required to redress this resource shortfall, particularly in
relation to dramatically improving staffing levels to, as a
minimum, at least return to the staff-to-population
ratios that prevailed in the mid-1990s [11]. This amount
was used to calculate the increase in unit costs that
would be required to achieve these quality improve-
ments prior to any increase in utilisation. This increase
in unit costs was phased in by 2015, whereafter real unit
costs are assumed to only increase by 1% per annum (i.
e. further expenditure increases would be driven largely
by increases in utilisation rates).
The national household survey did not provide ade-
quate data on the use of specialised hospitals (psychia-
tric, TB etc. hospitals). For this reason, a lump-sum
amount was added for these services, based on current
expenditure on these hospitals with increased resourcing
comparable to that outlined above for other health ser-
vices. Other services such as community-based services,
emergency medical services (ambulances etc.) and train-
ing of health professionals were also added on to the
total resource requirements projected by the model. In
addition, additional administration costs were included.
The ASSA2003 projections of population growth, dis-
aggregated using the same age/sex categories as for utili-
sation, were used. We assumed that while the entire
population would be eligible for benefits from the UC
system, a portion of the population will choose to main-
tain private health insurance and only draw on 25% of
the benefits of the UC system.
Estimates of GDP growth
We have estimated GDP growth over the period based
on National Treasury’s assessment of the economic out-
look in early 2010 [34], with a conservative extrapolation
into the future. Treasury estimated that real GDP
growth was 3.7% in 2008 and -1.8% in 2009 and pro-
jected it would increase by 2.3% in 2010, 3.2% in 2011
and 3.6% in 2012. The assumed real GDP growth rate in
future is:
➤ 4% in 2013 and 2014; and
➤ 4.5% from 2015 to 2020
These growth rates are considerably lower than the
real GDP growth rates of 5% or above experienced
between 2005 and 2007 (National Treasury 2009).
All ART costs, UC resource requirements and GDP
estimates are presented in real terms in 2007 US$.
Results
ART annual and total resource needs
If high coverage of ART is achieved and sustained, the
annual amount required is expected to increase from US
$1 billion in 2010 to US$3.6 billion in 2020, which is
close to a three-fold increase in total spending across the
period. The 43% increase needed from 2009 to 2010 stea-
dily decreases over the period to stabilize at a level of
around 6% per annum by 2020. During the same period,
the number of patients surviving and remaining in care
on ART is estimated to rise from 1 million to 3 million.
These results are summarized in additional file 3.
ART resource needs as a proportion of the current public
health system
During the calendar year of 2007, approximately US$8.7
billion was spent in the public healthcare system [35], of
which around 4% would have been required to support
the ART programme and related care (inpatient care,
treatment for tuberculosis etc). If high coverage of those
in need of ART is maintained and if the growth in fund-
ing to the public healthcare system keeps pace with pro-
jected real growth in GDP, then close to 30% of these
resources would be required for ART by 2020 (see addi-
tional file 4).
Annual resource requirements for UC
In order to redress the substantial under-resourcing of
the public health sector over the last decade and a half,
public funding as part of the UC reforms (excluding
resource requirements for those on ART) will need to
increase rapidly until 2015, by which time expenditure
of approximately US$17.6 billion would be needed.
Thereafter, resource requirements will increase more
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gradually, largely related to utilization increases, until a
level of US$22 billion is reached in 2020.
ART resource needs within the context of UC
The UC scenario, including ART costs, modeled in this
paper requires more than a doubling of total system
expenditure in real terms from 2010 to 2020. Increases
are phased in rapidly initially, with 12% higher real
expenditure in 2011 versus 2010. These increases
decrease over the period, to reach around 5% by 2016
and 4% by 2020. ART expenditure is 12.7% of total
expenditure over the period, ranging from nearly 9% in
2010 to slightly over 14% in 2020. Total annual expendi-
ture will be approximately US$25.6 billion by 2020. See
additional file 5.
Additional file 6 illustrates the implications of this
level of public funding of health services, including the
costs of those on ART. Expenditure on the UC system
will need to be about 4% of GDP by 2010 and increase
rapidly to 5.6% of GDP by 2015 and more gradually
thereafter to 5.7% of GDP by 2020.
Discussion
This paper has examined the overall costs of scaling up
access to ART from 2010 to 2020 within the context of
the proposed UC system. Coverage has been defined fol-
lowing the National Strategic Plan for HIV&AIDS and
STIs to be meeting 80% of new need for ART on an
ongoing basis. The costing of ART is subject to a num-
ber of key uncertainties including those related to the
data requirements of the study, extrapolation of data
and generalizability of results. Uncertainty relating to
data requirements has previously been assessed using
probabilistic sensitivity analysis (PSA) while generaliz-
ability has been assessed via multi-way sensitivity ana-
lyses [25]. While these analyses lend some support to
the overall robustness of the lifetime costs of care used
in this current analysis, it is nevertheless the case that
this costing is based on a relatively efficient model
where care is delivered via community health centers
and treatment is handled by both doctors and nurses.
This model of care is cheaper than a number of alterna-
tives that have been evaluated in the South African pub-
lic [36] and private healthcare sectors [37]. It should
therefore be borne in mind that the ART costs pre-
sented in this paper could be underestimated, given that
a scaled up response is likely to require delivery of ART
through all possible models of care. It is also likely that
costs would increase following any decision to change
the CD4 initiation criteria from <200 to <350 cells/μl.
While starting ART at CD4<350 cells/μl will be likely to
be associated with lower costs during the first year on
treatment [37], cost-effectiveness analyses have shown
that lifetime costs would increase, primarily owing to
higher life expectancy [38,39]. There is an urgent need
to model the implications of this change, which would
require data on lifetime costs from a generalizable
model of care, estimates of numbers in need as well as
an indication of the likely demand for this care under
different extensive HIV-testing scenarios. On the other
hand, if the steady decrease in ARV prices of the last
decade is maintained and the exchange rate deprecia-
tions resulting from the financial crisis abate, then some
of the costs could be overestimated in this paper.
Two scenarios have been explored in this paper. In
the first, resources in the public healthcare system are
assumed to stay constant in real terms at the 2007 level.
Under this scenario, scaling up access to ART would
consume 27% of these resources by 2020. In the second
scenario, the resources required to provide ART were
contrasted against the overall public resources available
if a UC health system were implemented, noting that
only one scenario is presented here which is simply
based on the resource requirements to improve the
quality of public sector services and increase access to
and utilization of these services. The proportion of total
expenditure on ART would be a maximum of just over
14% in 2020 and an average of 12.7% over the period.
This seems a far more feasible challenge and would be
accompanied by measures to redress historical inequities
in the overall health system.
We acknowledge that: “A model is not a crystal ball; it
does not predict the future. Rather, models project a pos-
sible future state on the basis of observations and
assumptions on future conditions.” [30]. The UC sce-
nario we have presented here is only one of a series of
scenarios we have developed, and it is highly dependent
on the assumptions made (which are spelt out in the
technical annex). It represents what could be considered
the minimum resource requirements for a universal
health system which provides both financial protection
and access to needed health services for all. The focus
of this paper is not to consider in detail alternative ways
of achieving universal coverage in South Africa and
associated resource requirements. Instead, the intention
is to illustrate how different the challenge of scaling-up
ART is in the context of currently under-resourced pub-
lic health services compared to a context of a commit-
ment to improving the domestic public funding of
health services with a goal of achieving universal
coverage.
There will be a number of challenges in implementing
UC reform in South Africa. The extent to which the
allocation from general tax revenue to the health sector
can grow, without increasing income tax rates, is depen-
dent on continuing to achieve strong economic growth.
One potential source of increasing tax revenue is the
proposed removal of tax deductibility of medical scheme
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contributions, the value of which was estimated to be
almost US$ 2 billion in 2007 [40]. There will be a need
for careful phasing in of the changes to ensure that the
absorptive capacity of the health system is not exceeded.
Importantly, there will undoubtedly be opposition from
key interest groups, particularly private insurance groups
and providers and the highest income earners. Interna-
tional experience demonstrates that the policy process,
particularly in dealing with such opposition, will require
careful management [41-43]. In addition, careful design
of the universal coverage system is required to ensure
that it is affordable and sustainable within the South
African context. For example, high quality services at
the primary care level and stringent gatekeeping to spe-
cialist and hospital based services are essential, as are
appropriate provider reimbursement methods (e.g. capi-
tation with global budget caps if primary care services
are purchased from private providers).
Despite these challenges, the goal of sustaining ART
access through achieving public funding levels
approaching 5-6% of GDP, whether solely through gen-
eral tax allocations or from general tax complemented
by a mandatory health insurance contribution (or dedi-
cated health tax), is within the realms of what would be
regarded internationally as affordable and sustainable.
While many of the countries with expenditure levels of
5% of GDP or more within the public healthcare sector
are in the high-income country category, there are a
growing number of middle-income (and some low-
income) countries that have achieved these spending
levels. For example, Brazil has public funding for health-
care of 4.8% of GDP, Costa Rica a level of 5.1%, Cuba
5.5% and Colombia 6.7% of GDP [44]. In all of these
countries, there has been a strong commitment to pub-
lic funding of social services and striving to achieve a
universal health system.
The analysis presented here indicates that the challenge
of achieving high coverage of ART in South Africa within
existing public sector resource levels could be quite over-
whelming in countries with a large HIV-epidemic. There
is considerable potential for HIV interventions to
adversely impact on other needed health services, given
the urgency and magnitude of the need for such inter-
ventions. However, if scaling up ART access is consid-
ered within the context of overall health system reform
to achieve universal coverage, the challenge becomes less
daunting. Thus, there is value in also focusing policy
attention on moving towards universal health system
coverage rather than focusing exclusively on the resource
requirements for scaling-up ART access. While there is
an urgent need to meet the treatment needs related to
the HIV-epidemic (and other communicable disease epi-
demics), there is an equally urgent need to give more
attention to moving towards universal health systems.
The international experience of moving towards uni-
versal cover in high-income countries and middle-
income countries in Asia and Latin America does not
provide any insights into how this can be achieved
within the context of a large burden of HIV/AIDS.
Therefore, the proposed UC reform in South Africa
provides an important opportunity for monitoring and
evaluating efforts to meet the emergency of the HIV-
epidemic in the context of achieving a universal health
system.
What we do know from international experience is
that universal coverage can best be achieved through
having an integrated pool of public funds [45]. What is
urgently required in low- and middle-income – mainly
African – countries facing a large HIV-epidemic is to
focus attention on integrating public funds (whether
from general tax revenue, mandatory health insurance
contributions or donor sources) into a single pool and
to increasing these funds, particularly from domestic
sources, over time. Progress towards achieving the
Abuja target of 15% of general tax funds being devoted
to the health sector has been extremely limited [46].
This must be addressed, and other options such as dedi-
cated health taxes or mandatory health insurance contri-
butions considered in order to gradually increase
domestic public funding for health services. This is
important as donor funding can be unreliable and irre-
gular, sometimes varying considerably from year to year,
and is unlikely to be sustained at current levels in the
long-term. In addition, donor funding to African coun-
tries is heavily focused on the key communicable dis-
eases of AIDS, TB and Malaria. Universal health
systems are unlikely to be feasible without increased
domestic public funding, particularly if the goal of uni-
versalism is being pursued at the same time as scaling
up ART interventions. It is only when there is increased
policy attention on achieving a universal health system
that equitable ART access will be affordable and sustain-
able and will not compromise the goal of equitable
access to other health services.
Conclusion
Responding to the HIV-epidemic is among one of the
many challenges currently facing the new South African
democracy. Whether this response becomes a “resource
for democracy” [47 p. 497] or whether it undermines
social cohesiveness between rich and poor communities
will be partially determined by the steps that are taken
during the next ten years. Mooney [48] argues that a
country’s healthcare system is a reflection of the values
of its citizens. If this is the case, a successful response to
the HIV-epidemic within a health system that is funded
from a substantial and integrated pool of public funds
could contribute to moving from a past marked by
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highly unequal access to freedom and resources to a
future characterized by cohesiveness and solidarity.
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